Liver fibrosis progression in hepatitis c virus infection after seroconversion

JAMA Internal Medicine

Volumn 175, Issue 2, 2015, Pages 178-185

  Butt, Adeel A ^a,b   Yan, Peng ^b   Lo Re, Vincent ^c   Rimland, David ^d   Goetz, Matthew B ^e   Leaf, David ^e   Freiberg, Matthew S ^a,b   Klein, Marina B ^f   Justice, Amy C ^g,h   Sherman, Kenneth E ⁱ  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d ATLANTA VA MEDICAL CENTER   (United States)

^e VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^f MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^g VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^h YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS C ANTIBODY;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL ABUSE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASSESSMENT OF HUMANS; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DIABETES MELLITUS; DISEASE COURSE; DRUG ABUSE; FEMALE; FIBROSIS 4 SCORE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTENSION; IMMUNOASSAY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEROCONVERSION; VETERAN; CASE CONTROL STUDY; COMPLICATION; IMMUNOLOGY; LIVER CIRRHOSIS; LIVER FAILURE; MIDDLE AGED; TIME; VIROLOGY;

ADULT; CASE-CONTROL STUDIES; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HEPATIC INSUFFICIENCY; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 84922255243     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.6502     Document Type: Article

References (30)

1. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-Acquired hepatitis C in the United States. N Engl J Med. 1992;327(27): 1899-1905
2. Barrett S, Goh J, Coughlan B, et al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. Gut. 2001;49 (3):423-430
3. Soto B, Snchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-Acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997;26(1):1-5
4. Butt AA, Khan UA,McGinnis KA, SkanDerson M, Kent Kwoh C. Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. J Viral Hepat. 2007;14(12): 890-896
5. Butt AA, XiaoqiangW, BudoffM, Leaf D, Kuller LH, Justice AC. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis. 2009;49(2): 225-232
6. Butt AA,Wang X, Moore CM. Effect of HCV and its treatment upon survival. Hepatology. 2009; 50(2):387-392
7. Butt AA, McGinnis KA, SkanDerson M, Justice AC. Hepatitis C treatment completion rates in routine clinical care. Liver Int. 2010;30(2):240-250
8. Butt AA,Wang X, Fried LF. HCV infection and the incidence of chronic kidney disease.AmJKidneyDis. 2011;57(3):396-402
9. Erqou S, Mohanty A,McGinnis KA, et al. Hepatitis C virus treatment and survival in patients with hepatitis C and human immunodeficiency virus co-infection and baseline anaemia. J Viral Hepat. 2013;20(7):463-469
10. Mohanty A, Erqou S, McGinnis KA, et al. Therapy for hepatitis C virus infection increases survival of patients with pretreatment anemia. Clin Gastroenterol Hepatol. 2013;11(6):741-747
11. Sterling RK, Lissen E, Clumeck N, et al; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317-1325
12. Holmberg SD, Lu M, Rupp LB, et al; Chronic Hepatitis Cohort Study (CHeCS) Investigators. Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort. Clin Infect Dis. 2013;57(2):240-246
13. Li J, Gordon SC, Rupp LB, et al; Chronic Hepatitis Cohort Study (CHeCS) Investigators. The validity of serum markers for fibrosis staging in chronic hepatitis B and C [published online January 29, 2014]. J Viral Hepat. doi:10.1111/jvh.12224
14. Fultz SL, SkanDerson M, Mole LA, et al. Development and verification of a virtual cohort using the National VA Health Information System. Med Care. 2006;44(8)(suppl 2):S25-S30
15. Butt AA, Fultz SL, Kwoh CK, Kelley D, SkanDerson M, Justice AC. Risk of diabetes in HIV infected veterans pre-And post-HAART and the role of HCV coinfection. Hepatology. 2004;40(1):115-119
16. Kramer JR, Giordano TP, Souchek J, El-Serag HB. Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. J Hepatol. 2005;42(3):309-314
17. Goulet JL, Fultz SL,McGinnis KA, Justice AC. Relative prevalence of comorbidities and treatment contraindications in HIV-mono-infected and HIV/HCV-co-infected veterans. AIDS. 2005;19(suppl 3):S99-S105
18. Butt AA, Khan UA, Shaikh OS, et al. Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers. HIV Clin Trials. 2009;10(1):25-32
19. Lo Re V III, Lim JK, Goetz MB, et al. Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf. 2011;20(7):689-699
20. Hopf U, Mller B, Kther D, et al. Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol. 1990;10(1):69-76
21. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, MelpolDer JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology. 1991;14(6): 969-974
22. Tremolada F, Casarin C, Alberti A, et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol. 1992;16(3): 273-281
23. Koretz RL, Abbey H, Coleman E, Gitnick G. Non-A, non-B post-transfusion hepatitis: looking back in the second decade. Ann Intern Med. 1993; 119(2):110-115
24. Mattsson L, Snnerborg A,Weiland O. Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. Liver. 1993;13(5):274-278
25. TongMJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-Associated hepatitis C. N Engl J Med. 1995;332(22):1463-1466
26. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 1990;12(4, pt 1):671-675
27. Seeff LB. Natural history of hepatitis C. Hepatology. 1997;26(3)(suppl 1):21S-28S.
28. Sung KC, Wild SH, Byrne CD. Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. J Hepatol. 2014;60(5):1040-1045
29. Sigala B, McKee C, Soeda J, et al. Sympathetic nervous system catecholamines and neuropeptide Y neurotransmitters are upregulated in human NAFLD and modulate the fibrogenic function of hepatic stellate cells. PLoS One. 2013;8(9):e72928
30. Butt AA, SkanDerson M, McGinnis KA, et al. Impact of hepatitis C virus infection and other comorbidities on survival in patients on dialysis. J Viral Hepat. 2007;14(10):688-696